去纤维钠对肝小静脉闭塞病的疗效

On October 22, 2013, Defibrotide (Defibrotide) was approved for marketing by the European Union as the first DNA-derived anticoagulant for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation with renal or pulmonary insufficiency following hematopoietic stem cell transplantation.

Marketing authorization has been granted by the European Commission regarding defibrotide (sodium defibrotide) for the treatment of severe hepatic VOD in hematopoietic stem cell transplantation (HSCT). A phase 3 randomized controlled trial of defibrination to prevent hepatic VOD in pediatric transplant patients has also been completed. Defibrotide (Defibrotide) has been generally well tolerated; the most common adverse reactions observed during premarketing use for the treatment of hepatic VOD were bleeding, hypotension, and coagulopathy.

About VODVOD is a potentially life-threatening condition that commonly occurs as a significant complication of stem cell transplantation. Use as part of a stem cell transplant may damage the cells lining the liver blood vessels and cause VOD, leading to liver failure, and may lead to significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD) due to obstruction of the hepatic venules. Hematopoietic stem cell transplantation is a frequently used treatment modality for blood cancers and other conditions in adults and children. English name: Defibroside (sodium defibration), trade name: Defitelio, Chinese name: sodium defibration, physical properties: oligonucleotide mixture, active ingredient composition: each ml contains active ingredient defibration sodium 80mg; and inactive ingredient sodium citrate 10mg, appropriate amount of pH regulator hydrochloric acid, sodium hydroxide to adjust pH to 6.8~7.8.

Recommended usage and dosage of defibrotide (sodium defibrotide): 1. Administer (sodium defibrotide) 6.25 mg/kg every 6 hours as a 2-hour intravenous infusion. 2. The total duration of treatment is a minimum of 21 days. If the signs and symptoms of VOD do not resolve after 21 days. Continue treatment until resolution. Mechanism of action: Not yet clear, it can enhance the enzymatic activity of plasmin in vitro and hydrolyze fibrin clots.

Recommended related hot articles: /newsDetail/83355.html